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The chemical susceptibility of the b-diketone linker between the two aromatic rings in the structure of
curcumin to hydrolysis and metabolism has made it crucial to investigate structurally modified analogs
of curcumin without such shortcomings. The synthesis of twenty cyclic C5-curcuminoids is described in
this study in order to gain more insight into their anticancer structure-activity relationship (SAR). The
design of their synthesis included four different cyclanones and five substituted aromatic aldehydes to
form four, five-membered subgroups. These model compounds were evaluated in vitro for anti-
proliferative activity in an XTT cell viability assay against MCF-7 human non-invasive breast adenocar-
cinoma cancer cells and Jurkat human T lymphocyte leukemia cells in five different concentrations
(10 nM, 100 nM, 1 mM, 10 mM and 20 mM). The majority of the compounds investigated have shown
remarkable cytotoxicity with IC50 values in the range of 120 nM and 2 mMwith very high relative toxicity
values to curcumin. The SAR conclusions are drawn and summarized. A method was developed and
applied in a TLC based experimental logPmeasurement, which is new for such C5-curcuminoids. The logP
data and structural modifications have shown a strong correlation. The correlation of these experimental
logP and the corresponding IC50 values of the model-compounds were calculated according to the
Pearson and Kendall correlation coefficient and showed weak concordance. The physicochemical be-
haviors of the majority of these compounds are in good accordance with Lipinski’s rule. The most
promising compound is 7a, which is the most active (IC50 ¼ 0.12e0.32 mM), most potent (80 times of
curcumin) with the lowest lipophilicity (experimental logP ¼ 3.22) which is important also from a
pharmacokinetic point of view. The analysis of experimental logP and computed ClogP values have
revealed good agreement. These cyclic C5-curcuminoids in contrast to curcumin do not bind to natural
DNA based on their CD spectra.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Plants are unbeatable sources of nutraceuticals. They are also
considered to be one of the major sources of lead molecules and
drug candidates [1]. The intense yellow rhizome of herbs in the
Zingiberaceae (ginger) family provides turmeric. Species like Cur-
cuma longa L. and/or Curcuma domestica L. for example, are used to
prepare that well-known spice nowadays. The major component ofB.V. This is an open access article uturmeric is its secondary metabolite, curcumin (Fig. 1). The pre-
ventive and therapeutic applications of curcumin are extremely
diverse. Many clinical trials have been conducted to evaluate their
pharmacokinetics, safety and efficacy. In cancer, cardiovascular
diseases, diabetes, inflammatory diseases and communicable dis-
eases, chronic arsenic exposure and alcohol intoxication, curcumin
has been analyzed [2].
Extensive research has shown that curcumin exhibits many
different pharmacological effects and has a number of molecular
targets with multiple pathways as an antiproliferative molecule
[3,4]. Curcumin (diferuloylmethane), 1,7-bis(4-hydroxy-3-nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Natural curcumins and synthetic homocyclic or heterocyclic C5-curcuminoids.
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(1,6-heptadien-3,5-dion) containing seven carbon atoms (C7) be-
tween the two arylidene groups in its structure (Fig. 1). It was a
belief for a long time, that natural curcuminoids (including the
metabolites of curcumin) are exclusively C7-curcuminoids. How-
ever, along with curcumin, a C5-curcuminoid was also isolated from
both Curcuma longa and Curcuma domestica [5,6]. This natural C5-
curcumin [7], 1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-
pentadiene-3-one, as a truncated analog of curcumin contains a
C5 ß-dienone linker (1,4-pentadiene-3-one) between the two
benzylidene cores in its structure (Fig. 1).
This compound, C5-curcumin and its related derivatives proved
to be more potent anticancer molecules compared to curcumin
[7,8]. Their interesting reversible thia-Michael reaction, which is
principal in binding to the biological place of action of such cur-
cuminoids is described in detail [8].
In view of the discovery of C5-curcumin showing superior
anticancer activity to curcumin, a number of new cyclic C5-curcu-
minoids have been synthesized. Structural modifications of C5-
curcuminoids focusing on enhancing their bioactivities have been
investigated intensively during the last couple of decades. Curcu-
min, C5-curcumin and cyclic C5-curcuminoids were subjected to
structure-activity relationship (SAR) studies [3,6e9] in order to find
details on the most appropriate structural changes for the best
cytotoxic effect.
The synthetic, cyclic C5-curcuminoid with a cyclohexanone core
(Fig. 1) for example proved to be more active against castration-
resistant prostate cancer compared to curcumin both in vitro and
in vivo [9]. Numerous studies have been conducted also on the
(3E,5E)-3,5-dibenzylidene-4-piperidone synthetic, heterocyclic C5-
curcuminoid family [10e15]. It became clear about these 4-
piperidone derivatives that they exhibit higher cytotoxicity than
curcumin towards different tumor cell lines like breast, prostate,
cervix, melanoma, etc. [3]. Compound EF31 for example (Fig. 1),
similarly to related derivatives is shown to be a pleiotropic inhibitor
of kinases (relevant to many forms of cancer), that operate at
multiple points along cell signaling pathways. In addition to su-
perior cytotoxicity to curcumin, these 4-piperidone derivatives
show differential cytotoxicity; they are less toxic to non-cancer
cells when compared to cancer cells [10,13,16,17].
Another crucial advantage of these synthetic C5-curcuminoids is
that a number of them are able to revert multi-drug resistance
(MDR) [14,16,17]. Moreover, there are reports on the in vivo toler-
ability and lack of acute toxicity of these curcuminoids on rodents
[18]. A number of C5-curcuminoids have several different modes of
action, such as inducing apoptosis, cell cycle arrest, inhibiting the
biosynthesis of polypeptides fundamental to tumor-progression,
affecting mitochondrial respiration and stimulation/inhibition ofcertain enzymes playing a role in tumor growth [19].
These cyclic C5-curcuminoids bear a b-dienon cross-conjugated
moiety essential for cytotoxicity [22] in their structure. This b-
dienon function is a reactive and selective Michael-acceptor [8].
Selectivity appears in the fact that the Michael-reaction takes place
exclusively with the nucleophilic thiol groups of biological mac-
romolecules. It seems to be logical, that these curcuminoids cannot
react with DNA in contrast to curcumin [20,21]. To gain details and
proof of their mode of action in this respect we decided to perform
CD spectroscopic investigations. Such CD spectroscopic data about
the cyclic and heterocyclic C5-curcuminoids are not available in the
corresponding literature to our knowledge. In view of the consid-
erations above as a continuation of our previous SAR studies
[22,23], and to gain more insight into the influence of structural
modifications on the cytotoxic activity of such homocyclic and
heterocyclic C5-curcuminoids we resynthesized twenty previously
described molecules (see experimental part) for a systematic SAR
study. These C5-curcuminoids are less susceptible to metabolism
compared to curcumin [24,25]. We selected the following two cell-
lines to perform XTT cell viability assays: MCF-7 (human non-
invasive breast cancer cells) and Jurkat (human T lymphocyte leu-
kemia cells). We applied an RP-TLC method to measure the
experimental logP values of the twenty selected molecules. Some
physicochemical parameters of the molecules were also computed




For the synthesis of themodel compounds of this study, we have
used a previously described “one pot” method of ours [22]. These
compounds are known from the chemical literature and were
prepared according to knownmethods, like 6a [38], 6b, 6c, 6d [39],
6e [40], 7a, 7d, 7e [41], 8a, 8d [42] and 8e [43]. We have recorded
their 1H NMR spectra and measured their melting points. Our own
physical data are in good accordance with the published parame-
ters. Chemicals, solvents and reagents for the studywere purchased
from Alfa Aesar, Molar and Merck Ltd (Budapest, Hungary). Melting
points were determined on a Barnstead-Electrothermal 9100
apparatus and are uncorrected. Silica gel 60 (0.2e0.5 mm, MERCK)
was used for column chromatography and pre-coated silica gel 60
(F-254, MERCK) plates for TLC.
NMR: 1H NMR spectra were obtained using a Varian UNITY
INOVA 400 WB spectrometer. Chemical shifts are referenced to the
residual solvent signal. Measurements were run at a probe tem-
perature of 298 K in CDCl3 or DMSO‑d6 solutions. All the 1H NMR
Fig. 2. Synthetic homo- and heterocyclic C5-curcuminoid model compounds 6e9 with
four different cyclanone cores and five aromatic substituents.
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2.2. CD
CD and UV measurements were performed on a Jasco J-720
spectropolarimeter (Jasco LtD., Tokyo, Japan) in Jasco cylindrical
cuvettes with a path length of 10 mm. 1 mg of chicken erythrocyte
DNA (Reanal, Budapest, Hungary) was dissolved in 10 ml distilled
water (stock solution, 0.1 mg/ml) and was further diluted to
0.033mg/ml for the experiments. Tested substances were dissolved
in DMSO (Sigma-Aldrich, Budapest, Hungary) in 5e10 mM con-
centration. All experiments were performed at ambient
temperature.
2.3. Physicochemical calculations
For the prediction of some physicochemical parameters of our
compounds, we have used the Calculator Plugins of ChemAxon. The
ClogP values were calculated with all three methods and database
of the software. The ClogP and solubility values are results in
physiological pH ¼ 7.4. See the corresponding homepage for
detailed conditions of the calculations [33]. To explain the rela-
tionship between biodata and calculated physicochemical param-
eters the Lipinski approaches have been used [32].
2.4. Cell culture
MCF-7 human non-invasive breast adenocarcinoma cancer cells
[26] were cultured in DMEM medium with 4.5 g/l glucose and
2 mM L-glutamine (Lonza, Verviers, Belgium). Jurkat human T
lymphocyte leukemia cells [27] were cultured in RPMI 1640 me-
dium with 2 mM L-glutamine (Lonza). All media were supple-
mented with 10% heat-inactivated FBS (Sigma, St. Louis, MO) and
antibiotics 10 ml/l (penicillin-streptomycin 100 x, Sigma, St. Louis,
MO).
2.5. Cytotoxicity test
Following the protocol of XTT cell viability assay (Biotium,
Hayward, CA), the concentrations were 50.000 cells/ml (MCF-7)
and 100.000 cells/ml (Jurkat) in the above described supplemented
media. 100 ml of cell suspension was placed into each well of 96-
well plates and incubated for 48 h in regular conditions (37 C,
100% relative humidity and 5% CO2). 5 ml solutions of curcumin and
its analogs diluted in DMSO (Sigma, St. Louis, MO), added to each
well to reach 10 nM, 100 nM, 1 mM, 10 mM and 20 mM final con-
centrations. After 24-h incubation in regular cell culture conditions,
25 ml activated XTT solutionwas mixed with media in the wells and
consecutively incubated for 3 h. Finally, the absorbance was
measured at a wavelength of 490 nm with DiaReader ELx800
(Dialab, Vienna, Austria) microplate reader. Results of curcumin and
its analogs were compared to the DMSO controls with Student’s t-
test and statistical significance (p < 0.05) was calculated.
2.6. Experimental (logP)
RP-TLC logP determinations were performed by a slight modi-
fication of the previously optimized RP-TLC method used for
determination of some chalcones and cyclic chalcone analogs
[28,29]. Compounds of the calibration set (selected chalcones and
cyclic chalcone derivatives, see the structures in “Supportive ma-
terial”) were synthesized and purified as described [37]. Their logP
values were determined earlier [28,29]. Two compounds of the
validation set (progesterone, diazepam) were of pharmacopoeial
grade. All other reagents used were of analytical grade.RP-TLC determination of the logP of the cyclic C5-curcuminoid
compounds 6e9 was performed on 20 cm  20 cm plates pre-
coated with 0.25 mm layers of silanized silica gel 60F254 (Merck,
Germany; #5747). The plates were washed with methanol and
dried before use. The samples of 6e9 were dissolved in 1:1
methanol-chloroform (c ¼ 1 mg/cm3) and 2 ml of these solutions
were spotted on the plate. Methanol-water, 70þ 30 (v/v), was used
as mobile phase. The paper-lined chromatographic chamber was
saturated with the mobile phase for 30 min before use. After
development (150 mm) the plates were dried and the chromato-
grams assessed visually under UV illumination (l ¼ 254 nm). Three
TLC determinations were performed for each substance.
Some of the investigated molecules contain weakly basic func-
tional groups. It was found, however, that they occur as non-
ionized, neutral species under the experimental conditions.
2.7. Validation of the RP-TLC system
The optimized chromatographic system underwent validation
prior to logP measurements. For this purpose, four molecules
(progesterone, diazepam, chalcone and a chalcone derivative (Q-
693)) with known logP values were tested. Comparison of their
logPTLC values obtained in this work with previously published
experimental logP data [28] resulted in rather good agreement.
Thus, these four compounds were also added to the calibration set.
The logPTLC data obtained by our optimized and validated RP-
TLC method are listed in Table 6. The logP data can provide a
good basis for evaluation of structure-lipophilicity relationship for
the examined compounds 6e9. See “Supplementary data” for more
details.
3. Results and discussion
3.1. Chemistry
The synthesis of our model compounds 6e9 for this SAR study
was performed according to known methods involving the condi-
tions of a Claisen-Schmidt condensation as depicted in Fig. 2. The
nitrogen containing heterocyclic derivatives 7 and 8 have been
prepared according to our new “one-pot” synthesis [22] starting
from the corresponding b-ketoesters and aldehydes. Condensation
reactions were carried out under basic or acidic conditions in good
yields in a range of 75e90%. Formally, four different cyclic ketones,
like 4-methylcyclohexanone (1), 4-piperidone (2), N-methyl-4-
piperidone (3) or 4-hydroxycyclohexanone (4) and always the
Table 1
In vitro antiproliferative activities of model-compounds against Jurkat and MCF-7
cancer cell lines in terms of their IC50 (the concentration that causes a 50% cell
proliferation inhibition) values in micromoles and relative potentials related to
Curcumin.
Compound Jurkat MCF-7
IC50[mM] Relative pot.a IC50[mM] Relative pot.a
Curcumin 0.95 1.00 9.76 1.00
6a 0.40 2.38 0.49 19.92
6b 6,59 0.14 17.00 0.57
6c 4.00 0.24 9.80 0.996
6d 2.89 0.33 8.77 1.32
6e >20 not relevant >20 not relevant
7a 0.32 2.97 0.12 81.33
7b 0.36 2.64 >20 not relevant
7c 0.24 3.96 0.81 12.34
7d 10.32 0.09 5.87 1.66
7e 0.14 6.79 9.80 0.996
8a 1.00 0.95 0.75 13.32
8b 0.21 4.52 0.43 22.70
8c 1.49 0.64 2.38 4.31
8d 9.32 0.10 >20 not relevant
8e >20 not relevant >20 not relevant
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cross-aldol condensation reactions to form the desired model
compounds 6e9. Cyclanone 4 was prepared accordingly to our
previously published method [23].
Our goal was on the one hand to prepare target compounds 6e9
with a small substituent in the central ring (X ¼ CH-CH3, N-H, N-
CH3 or CH-OH) due to the fact, that derivatives 7b and 7c (Fig. 3)
turned out to be very promising antiproliferative agents. They have
even been selected as standard lead compounds to be compared to
newer promising agents [22 and references therein]. We selected
five substituents onto the aromatic rings (nitro, chloro, hydrogen,
methoxy, dimethylamino) on the other hand, in order to find the
most optimal structure from the SAR analysis with the two sub-
stituents in the central and aromatic rings. In Fig. 3 we can see the
structures of the twenty cyclic C5-curcuminoid derivatives pre-
pared for this study. Compounds 7b, 7c, 8b, 8c [22] and 9a-e [23]
were prepared by us previously together with the others (6a-e, 7a,
7d, 7e, 8a, 8d and 8e, see the experimental part) are in good
accordance with the literature data in terms of their melting points
and 1H NMR spectra.9a 0.88 1.37 1.64 5.95
9b 1.99 0.48 >20 not relevant
9c 2.30 0.41 8.71 1.32
9d 10.50 0.09 11.31 0.86
9e 19.85 0.05 >20 not relevant
a Relative potential: IC50 value of curcumin divided by the IC50 value of the
compound.3.2. Cytotoxicity
The synthesized compounds were evaluated for their in vitro
antiproliferative activity against MCF-7 human non-invasive breast
adenocarcinoma cancer cells [26] and Jurkat human T lymphocyte
leukemia cells [27] in an XTT cell viability assay. Inhibition of cell
proliferation by these active compounds at various concentrations
(10 nM, 100 nM, 1 mM, 10 mM and 20 mM) was measured, and their
IC50 (the concentration that causes a 50% cell proliferation inhibi-
tion) values were calculated and are summarized in Table 1.
It was observed generally, that Jurkat leukemia cells were more
susceptible to cytotoxic treatment in almost all cases compared to
MCF-7 cells (Table 1). We have observed in eight cases, that the
given compound was practically ineffective. Compounds 6e and 8e
were ineffective on both cell lines. Although we did not use non-
cancer cells for cytotoxicity tests, the difference in susceptibility
of the two cell lines and of ineffective cases of these compounds is
proof of their selective toxicity. We can state, however, that the
majority of these compounds proved very good activity on cyto-
toxicity/viability tests. Many of them like 6a, 7a, 7b, 7c, 7e, 8a, 8b
and 9a (6a, 7a, 7c and 8b on both cell lines) were active even in the
nanomolar range.
Moreover, many of them showed superior cytotoxic activity to
Curcumin, namely compounds 7e, 8b, 7c, 7a, 7b and 6a on JurkatFig. 3. Structures of the twenty homo- and heterocyclic C5-curcuminoids prepared for
this SAR study.cells while compounds 7a, 8b, 6a, 8a and 7c on MCF-7 cell line. The
previous sequence is important because it shows also the ranking of
their IC50 values. The IC50 values of the most active compounds on
Jurkat cells are between 0.14 (7e) and 0.40 (6a) mM while 0.12 (7a)
and 0.81 (7c) mM on MCF-7 cells.
The relative potential, which shows the rate of dominance over
curcumin of compounds in Table 1, is higher on MCF-7 cell lines in
general. For example, 7e on Jurkat and 7a on MCF-7 cells have a
similar IC50 value (0.14 and 0.12 respectively), but the relative po-
tential is different. It is 6.79 for 7e on Jurkat and 81.33 for 7a on
MCF-7. This means, that 7a is the most potent congener compared
to curcumin. It is important to emphasize, that derivatives 6a, 7a, 7c
and 8b possess cytotoxicity on both cell lines. We can draw a very
positive conclusion that our model compounds are showing se-
lective toxicity with different relative potentials.
The b-dienone moiety, which serves as the primary pharmaco-
phore function (Fig. 4, A) in the structure of our compounds 6e9 is
the same in all derivatives. In order to compare changes in activity
after structural modifications on the central ring and on the aro-
matic benzylidene rings we have created a “heat-map” including
the structures of the compounds with substituents on the central
and aromatic rings, IC50 values of our cyclic C5-curcuminoids andFig. 4. The primary (A) and secondary (B) pharmacophore functions of cyclic C5-
curcuminoids.
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proliferative activity) are in red whilst the bigger IC50 values (lower
activity) are in blue. The others in between are in yellow and green.
Our first conclusion is that the heterocyclic derivatives 7 and 8
exhibitedmore pronounced antiproliferative activities compared to
their homocyclic counterparts 6 and 9. This fact promotes our
earlier findings [22,23] on such heterocyclic C5-curcuminoids
including compounds 7b, 7c, 8b and 8c [22] or 9a-e [23]. The
reference standard was cisplatin in both of these two studies. The
position opposite to the ketone carbonyl on the central cyclanone
ring, being an auxiliary binding ability (secondary pharmacophore,
Fig. 4, B) to the in vivo biological site of action, has a great influence
on the cytotoxicity of these compounds. In other words, the binding
strength of these cyclic C5-curcuminoids to the biological site of
action is stronger when there is a suitable substituent and/or a
nitrogen heteroatom at this position. This moiety on the central
cyclanone ring (Fig. 4, B) is able to enhance the interaction between
the cyclic C5-curcuminoids and their biological place of action in
the cancer cell. This is visible on the example of 6b and 8b: the
cytotoxic activity increases on both cell lines (see the correspond-
ing IC50 values) after the nitrogen atom “appears” in the homocycle
of 6b to form the heterocyclic 8b counterpart (Table 2). A similar
example is the exchange of the NH functional group of compound
7c to an OH in 9c.
The second conclusion is that the electronwithdrawing p-chloro
and especially p-nitro substituents on the benzylidene parts are
dominating the p-methoxy or p-dimethylamino electron donor
substituents. For example, compound 6awith a nitro group showed
0.40 mM IC50 value on Jurkat cells, whilst 6e with a dimethylamino
substituent was practically ineffective. The same is true on the
MCF-7 cell line about 6a and 6e. Apart from some exceptions,
similar examples are there in Table 2. A definite structure/activity
relation was discovered comparing the average IC50 values of the
five substituents (nitro, chloro, hydrogen, methoxy and dimethy-
lamino) on benzylidene moieties (Table 2). The best performer is
the nitro-substituted benzylidene group (6a, 7a, 8a and 9a) with
IC50 values ranging from 0.12 to 1.64 mM. The second in this
sequence is the unsubstituted benzylidene group (6c, 7c, 8c and
9c), the third is the chloro-substituted 6b, 7b, 8b and 9b. The last
two positions remain to the methoxy (d) and dimethylamino (e)
substituents with average IC50 values of 8.43 and 9.93 mM
respectively.
Experimental and calculated data in Tables 1 and 2, in relation to
the two moieties A and B (Fig. 4) suggest that there is an electron
withdrawing substituent on the benzylidene groups and a nitrogen
heteroatom in the optimal structure for the optimal anti-
proliferative activity. From this SAR analysis, it is noteworthy thatTable 2
The IC50 “heat-map” of compounds 6e9. Curcumin IC50: Jurkat e 0.95; MCF-7 e 9.76 mMwe could not find (apart from a few exceptions like 6a, 7a or 6e, 8e)
a very strong relationship between the IC50 values of the two cell
lines. The two cell lines correlate neither the Pearson correlation
nor the Kendall coefficient of concordance. Our results on the cor-
responding calculations showed a Kendall coefficient match bigger
than 1. It was 1.75, which may mean interestingly two different
ways of biological action on the two different cancer cell lines.
3.3. Physicochemical investigations
3.3.1. Experimental logP (logP)
On the basis of our former results [28,29], we designed and
performed experiments in order to obtain experimental logP values
of cyclic C5-curcuminoid compounds 6e9. The method we devel-
oped, validated and applied is a chromatographicmeasurement in a
reversed phase thin-layer chromatographic (RP-TLC) setting. The
theoretical base for the determination of logP by chromatographic
methods is the relation between the partition coefficient
(measured with a shake-flask) and a chromatographic retention
parameter (RM for RP-TLC) based on liquid/liquid partition. RM
values (calculated using Rf) are in a linear correlation with logP
values in a suitable chromatographic system according to the
logP¼ aRM þ b
equation. The essence of chromatographic logP determination is
thus the determination of the regression parameters of the above
equation by using a set of standards (calibration set) with known
octanol/water logP values. Based on this equation the experimental
logP of other compounds can be calculated. See experimental for
details.
Results from the RP-TLC measurements for experimental logP
data are summarized in Table 3. These data revealed a clear,
consistent structure dependency of the measured logP values. The
model molecules are highly lipophilic, as might be expected from
their chemical structures. They contain an extended lipophilic
carbon skeleton with aromatic moieties, which are compensated
only a little bit by the polarity of the carbonyl group. Polarity of the
structures is under slight influence also by the aromatic
substituents.
Apart from some exceptions like 7e or 9a, lipophilicity is
decreasing in the sequence of 6, 7, 8 and 9. This tendency is visible
in general (see the average values) and in parts (see the rows in
Table 3). On the other hand, lipophilicity is growing from nitro
toward dimethylamino substituent (see the columns in Table 3) in
the sequence of a, c, d, b and e along with exceptions like 7d or 9a.
The exceptions mentioned before are due to a possible self-
dimerization with H-bonds of compounds 7 or 9 respectively,.
Table 3
Experimental logP values (±sample standard deviation), determined by RP-TLC method.
Compounds:
6: 7: 8: 9:R ¼
a: eNO2 4.70 ± 0.01 3.22 ± 0.30 3.31 ± 0.03 3.62 ± 0.02
c: eH 5.82 ± 0.06 4.11 ± 0.17 4.14 ± 0.04 3.36 ± 0.01
d: eOCH3 5.98 ± 0.07 5.10 ± 0.32 4.57 ± 0.06 3.57 ± 0.04
b: eCI 6.40 ± 0.05 4.75 ± 0.12 5.01 ± 0.09 4.28 ± 0.01
e: eN(CH3)2 6.75 ± 0.07 7.29 ± 0.02 5.69 ± 0.15 4.04 ± 0.13
Average: 5.93 4.89 4.54 3.77
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possible dimerization makes them less polar and so more lipophilic
under the conditions of the measurement. The most lipophilic
substance is 7e with an extreme high logP value.
Our goal was also to determine if there was a correlation be-
tween the obtained logP data and the pharmacological activity of
model compounds 6e9. Therefore, we collected the experimental
logP and the corresponding IC50 values intoTable 4. In order to have
a more detailed insight, the data from Table 4 underwent calcula-
tions according to Pearson correlation and Kendall coefficient of
concordance. As a result of our calculations, we may conclude, that
there was no consistent linear or logarithmic relation that could be
established between antiproliferative activity and lipophilicity of
our model compounds in this study. This fact does not mean,
however, that there is no positive correlation between the nature of
the structure and the biological activity at all.
We can state for example that compounds with IC50 value under
themedian value of 2.15 mM Jurkat or 9.29 mMMCF-7 (whichmeans
good antiproliferative action) together with lower logP value of the
median 4.63 are promising molecules. Compounds like this in
Table 4 are 7a, 7c, 8a, 8c and 9a under Jurkat line or 7a, 7c, 8a, 8c, 9a
and 9c under the MCF-7 line. The logP of these most effective
compounds are in the range of 3.22 and 4.63. There are derivatives
with higher logP value, which are practically ineffective compounds
like 6e or 8e. There is only one compound (7e) in conflict with this
(Table 4). The majority of these compounds are in good accordance
with Lipinski’s rule [32].
To visualize the relationship between experimental logP andTable 4
Collected experimental data from logP and IC50 measurements.
Compound logP IC50 [mM]
Jurkat MCF-7
6a 4.70 0.40 0.49
6b 6.40 6.59 17.00
6c 5.82 4.00 9.80
6d 5.98 2.89 8.77
6e 6.75 >20 >20
7a 3.22 0.32 0.12
7b 4.75 0.36 >20
7c 4.11 0.24 0.81
7d 5.10 10.32 5.87
7e 7.29 0.14 9.80
8a 3.31 1.00 0.75
8b 5.01 0.21 0.43
8c 4.14 1.49 2.38
8d 4.57 9.32 >20
8e 5.69 >20 >20
9a 3.62 0.88 1.64
9b 4.28 1.99 >20
9c 3.36 2.30 8.71
9d 3.57 10.50 11.31
9e 4.04 19.85 >20
Median: 4.63 2.15 9.29IC50 datawe have plotted them against each other. The diagrams on
the two cancer cell lines are in Fig. 5. The most promising com-
pounds are in blue. They have lower lipophilicity with higher
antiproliferative activity (smaller IC50 values). Derivatives repre-
sented with red spots are more lipophilic with lower activity,
except 6c, 6d and 7e on Jurkat cells. The most promising compound
is 7a, which is the most potent on both cell lines with the lowest
lipophilicity, which is also important from a pharmacokinetic point
of view.3.3.2. Predictive physicochemical calculations (ClogP, solubility in
water and 3D shape)
For an evaluation of some physicochemical properties
(compared to curcumin), the parameters of the synthesized com-
pounds were computed. Just as in our previous studies [22,23]
ChemAxon’s Marvin Suite Plugins were used for all of the calcula-
tions [33]. Calculated logP was determined according to three
different methods of Marvin’s calculator plus the average value
(Table 5).
Number of hydrogen bond forming ability of the structures,Fig. 5. Relationship between antiproliferative activity and lipophilicity of compounds
6e9. Experimental logP and IC50 data of the effective derivatives are plotted against
each other.
Table 5
Computed physicochemical parameters of the investigated compounds were undertaken. Calculated partition coefficient (ClogP) values were determined according to three
methods (VG, KLOP, PHYS) of Marvin Suite [33]. Predicted solubility at pH ¼ 7.4 of the compounds is considered to be “Low” in this table, when it does not exceed 0.01 and is
moderate if it was 0.01e0.06 mg/ml in water.
Compound MW VG ClogP PHYS Average logP H-bond Solubility IC50
KLOP (TLC) Jurkat MCF-7
6a 378.38 6.20 5.58 5.51 5.76 4.70 5 Low 0.40 0.49
6b 357.27 7.33 7.04 6.91 7.09 6.40 1 Low 6.59 17.00
6c 288.39 6.30 5.76 5.59 5.88 5.82 1 Low 4.00 9.80
6d 348.44 5.79 5.49 5.43 5.57 5.98 3 Low 2.89 8.77
6e 374.53 6.82 5.73 5.75 6.10 6.75 3 Low >20 >20
7a 365.35 4.30 3.65 3.39 3.78 3.22 7 Low 0.32 0.12
7b 344.24 5.43 5.11 4.78 5.11 4.75 3 Low 0.36 >20
7c 275.35 4.39 3.83 3.47 3.90 4.11 3 Low 0.24 0.81
7d 335.40 3.89 3.56 3.30 3.58 5.10 5 Moderate 10.32 5.87
7e 361.49 4.92 3.80 3.63 4.12 7.29 5 Moderate 0.14 9.80
8a 379.37 4.66 3.93 3.89 4.16 3.31 6 Low 1.00 0.75
8b 358.26 5.79 5.40 5.28 5.49 5.01 2 Low 0.21 0.43
8c 289.38 4.76 4.12 3.97 4.28 4.14 2 Low 1.49 2.38
8d 349.43 4.25 3.85 3.80 3.97 4.57 4 Low 9.32 >20
8e 375.52 5.28 4.08 4.13 4.50 5.69 4 Moderate >20 >20
9a 380.36 4.51 3.82 3.94 4.09 3.62 7 Low 0.88 1.64
9b 359.25 5.64 5.28 5.33 5.42 4.28 3 Low 1.99 >20
9c 290.36 4.61 4.01 4.02 4.21 3.36 3 Low 2.30 8.71
9d 350.41 4.10 3.73 3.85 3.90 3.57 5 Low 10.50 11.31
9e 376.50 5.14 3.97 4.17 4.43 4.04 5 Moderate 19.85 >20
Curcumin 368.13 3.95 3.65 3.68 3.76 4.12 9 Moderate 0.95 9.76
Table 6
LogPSF and logPTLC values of the compounds of the validation set.
logPSF logPTLC DlogP
Chalcone 3.62 3.62 0
Q693 3.74 3.77 0.03
Progesterone 3.54 3.67 0.13
Diazepam 2.82 3.05 0.23
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also calculated. We couldn’t find any rationale among the predicted
physicochemical data in Table 5 to explain the difference between
the antiproliferative activity of curcumin and our model com-
pounds 6e9. There are only some slight variations in the values of
the data listed in Table 5. This can not be the cause of the great
difference in pharmacological activity between curcumin and our
cyclic C5-curcuminoids. The reason for this must be somewhere
else, which leads us to investigate further in this direction.
Data in Table 5 together with our earlier findings [22,23] how-
ever show that the software [33] we used in our research is useful
and beneficial.
Computed structures were also cleaned into 3D shape by the
software used [33]. Compounds 8c and 9c as examples are available
in their “ball and stick” model without their hydrogen atoms in
Fig. 6. What we can see in general is that the two benzene rings in a
molecule are not in the same plane. It is also visible, that the centralFig. 6. “Ball and stick” 3D models of compouring (4-piperidone or 4-hydroxycyclohexanone respectively) is
located in a third plane. These three planes occupy a “close-to-
planar” molecular shape. It is important to note that the central
rings are almost planar. Only the atom opposite to the carbonyl
function is out of the plane in an envelope-like form. Finally, the
cyclic b-dienone moiety in this cross-conjugated system keeps the
conformation of these molecules fixed.
3.4. DNA binding
CD is a reliable tool for the detection of DNA binding of ligands,
like drugs or any other different molecules. The appearance of the
induced circular dichroism signal (ICD) is definitive proof of the
interaction. In addition, shifts in the DNA bands are also indicative
of the binding [34,35].
There is little known about the DNA binding of cyclic C5-cur-
cuminoids. However, we know more about curcumin in this
respect. It is known from in vitro experiments for example, that
curcumin appears in the nucleus of cultured glioma cells after in-
cubation. It was revealed that nuclear homing is not a result of
curcumin’s DNA binding [36]. The temporal relationship of curcu-
min’s apoptotic induction effect and its nuclear homing is under
investigation to acquire details about the mechanism of action. This
fact among others prompted us to initiate measurements to see
possible interactions between C5-curcuminoids and DNA. For this
reason, we conducted circular dichroism spectroscopicnds 8c and 9c without hydrogen atoms.
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in series 6e9 using natural DNA.
Curcumin, as well as 20 cyclic C5-curcuminoid derivatives 6e9
were tested on chicken erythrocyte DNS. In the CD spectrum of
curcumin, a large ICD band appeared in the ligand’s absorption
region, showing a strong interaction between the ligand molecule
and the chicken erythrocyte polynucleotide (Fig. 7). It also caused
some minor shift in the DNA band, meaning the double helical
structure is slightly distorted (Fig. 7). Those derivatives containing
either aliphatic or aromatic nitrogen showed signs of interaction - a
weak ICD sign appeared in the recorded spectra for example in the
case of dimethylamino substituted 6e, 7e, 8e and 9e (Fig. 7). DNA
bands did not change significantly at the same time, indicating that
the polynucleotide remains in its native B-form. The binding is
most probably the result of the weak ionic interaction of the ni-
trogen atoms from the cyclic C5-curcuminoid structure with the
phosphate groups of DNA. In the case of other derivatives with no
nitrogen atom in their structure neither an ICD signal, nor a shift in
the DNA bands was detected, indicating that no interaction occursFig. 7. Selected CD and UV titration of 0.033 mg/ml chicken erythrocyte DNA (black, lowe
trations are 16.66 mg/ml, 25 mg/ml and 33.33 mg/ml respectively). Strong interaction of curcum
or 9a.between the molecules and DNA (Fig. 7).
Although it would be consistent with an ability of these curcu-
minoids 6e9 to adopt a “close-to-planar” molecular shape (Fig. 6),
in contrast to curcumin, none of them showed stronger interaction
with the DNA used in this study. It would be conceivable that the
very active inhibitors in Table 2 show diverse interaction compared
to the practically ineffective counterparts (Table 1). However,
compounds in these series showed similar properties under CD
conditions that make it possible to generalize: based on these data
we conclude that these derivatives do not bind to DNA in vitro. Due
to this finding, we can disclose that the antiproliferative activity of
these cyclic C5-curcuminoids is not due to their interaction with
DNA.
The CD spectra of compounds 6e9 can be found in the “Sup-
plementary data” section.4. Conclusions
The chemical susceptibility of the b-diketone linker between thest curve) with 5 mM curcumin or cyclic C5-curcuminoid stock solution (final concen-
in, very weak interaction of 9e. The other derivatives remain intact, like for example 8a
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metabolism [24,25] has made it a crucial point to investigate
structurally modified analogs of curcumin without such short-
comings. These well-known shortcomings at the same time are the
possible reasons for the drawbacks in the bioavailability of curcu-
min [3]. On this basis and as a continuation of our former SAR
studies [22,23] we have designed and synthesized twenty cyclic C5-
curcuminoids (6e9), the truncated forms of curcumin in order to
have a deeper insight into the impact of structural modifications
over cytotoxic activity and/or physicochemical parameters of our
model compounds 6e9. The b-dienone linker of these C5-curcu-
minoids is stable and has the same role as the b-diketone moiety of
curcumin such as the primary pharmacophore function. We have
modified the polarity/lipophilicity of this b-dienone linker by
introducing five different substituents (nitro, chloro, hydrogen,
methoxy and dimethylamino, respectively) onto the aromatic rings
dividing the group (6e9) into five subgroups (a, b, c, d and e). The
four different cyclanons (1e4 in Fig. 2) divided the group of these
model compounds further into four additional subgroups (6e9).
The four subgroups have selected moieties in the central cyclanone
ring in the position opposite the carbonyl function, and these
moieties are filling the role of the secondary pharmacophore of
these compounds (Fig. 4). As a conclusion, we can state that the
structural modifications in the primary and secondary pharmaco-
phore of thesemodel molecules resulted in clear correlations in our
SAR analysis. Experimental and calculated data in Tables 1 and 2, in
relation to the two moieties A and B (Fig. 4) suggest that there is an
electron withdrawing substituent on the benzylidene groups and a
nitrogen heteroatom in the optimal structure for the optimal
antiproliferative activity. The IC50 values of the antiproliferative
activity dropped to the minimum compared to curcumin, even to
submicromolar in cases close to the optimal structure. The physi-
cochemical parameters such asmolecular weight, polarity, logP and
solubility of these compounds are in good accordance with Lip-
inski’s rule [32]. The most promising compound is 7a, which is the
most effective (IC50 ¼ 0.12e0.32 mM), most potent (80 times of
curcumin) with the lowest lipophilicity (experimental logP ¼ 3.22)
which is important also from a pharmacokinetic point of view.
There was no sign (or very weak if at all) of interaction between
cyclic C5-curcuminoids 6e9 and DNA in the CD spectra. Therefore,
we can also conclude that there is no risk for such possible and
serious side effects from this source in the case of these curcumi-
noids. This fact is an advantage over curcumin if we compare the
results of our circular dichroism (CD) investigations. These findings
increase the knowledge about such cyclic C5-curcuminoids in order
to find the optimal structure in terms of antiproliferative activity
and potential.
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